Perjeta

UK pharma rebate payment doubles in one year

First quarter repayment £138m higher than this time last year

Roche maintains dominance as leading cancer drugmaker

drugs such as its next-generation breast cancer drug Perjeta (pertuzumab). ... This was highlighted in England where last year the country's health technology assessor NICE said Perjeta was nearly double the price (at £90, 000) than it would consider

Roche adds kidney cancer to anti-PD-L1 programme

Sales of the company's HER2-targeting drugs - Herceptin (trastuzumab) and follow-up therapies Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine) - grew 23% thanks to increased use of Herceptin and Perjeta in ... The growth of Perjeta - up 82% to

England's Cancer Drugs Fund: Fixing a broken system

The Swiss firm has, in relative terms at least, not come out too badly during the de-listing process as two of its newer cancer medicines, namely breast cancer treatments Perjeta

Roche's newer breast cancer drugs gain traction

Perjeta and Kadcyla boost 2014 revenues. Solid growth for Roche's breast cancer blockbuster Herceptin was backed up by big gains for two follow-up products in the last quarter for ... Roche's breast cancer franchise was particularly boosted by the

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]